Post by norfoster on Oct 20, 2017 14:56:01 GMT
Mongersen drug was bought by Celgene for $710 million four years ago. Yesterday, Celgene announced that Mongersen had failed and it is going to halt the trials. But to SEC they have given the details of the financial impact in connection with the decision of stopping these trials. alphastreet.com/bce290d5